Dr. Jim Musick, Vitro's President and CEO, said, "The present advances in stem cell differentiation position the Company for additional commercial opportunities. We believe there is an unmet need for human beta islets in research and drug discovery applications. Our current efforts are directed towards further characterization of stem cell-derived beta islets produced by our newly discovered method and scale-up of production capacity to support anticipated initial commercial distribution."

There may also be therapeutic applications of stem cell technology in the treatment of diabetes. It has recently been shown that autologous bone marrow stem cell transplantation can slow the progression of early onset Type I diabetes probably by reducing autoimmune destruction of beta cells. A longer-term goal of the Company is to further develop its stem cell-derived beta islets for use in cell therapy of diabetes. The present advances may open opportunities to complete pre-clinical research studies and proceed with regulatory approval through the FDA, given the availability of adequate resources.

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG) http://www.vitrodiag.com, owns 29 patent-pending adult pancreatic stem cell lines that are distinct from the limited number of embryonic stem cell lines that are presently approved for federally funded research. These cell lines may have commercial application in diabetes research and therapy. The Company's reliance on adult stem cell lines obviates some ethical objections to embryonic stem cell research. Knowledge gained from its adult stem cell lines may also benefit studies of the differentiation of pleurapotent stem cell lines into human beta islets. The Company developed and manufactures the VITROCELL(TM) brand of human cell lines consisting of pituitary and pancreatic-derived cell lines and related products for various research and commercial applications.

Safe Harbor Statement

Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are often identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's Annual Report on Form 10-KSB for the fiscal year ended October 31, 2006 and other reports filed with the Securities and Exchange Commission under the caption, "Risk Factors." Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.